Methionine Adenosyltransferase II: Potential Drug Target Or Biomarker

Target Name: Methionine adenosyltransferase II

NCBI ID: P22630

Methionine adenosyltransferase II

Other Name(s): MAT II | S-adenosylmethionine synthetase 2

Methionine Adenosyltransferase II: Potential Drug Target Or Biomarker

Methionine adenosyltransferase II (MAT II), also known as MAT2, is a protein that plays a crucial role in the regulation of methionine levels in the body. Methionine is a crucial amino acid that is essential for the structure and function of many proteins, as well as for the maintenance of cellular health. However, MAT2 is responsible for breaking down the methionine that is synthesized in the body, ensuring that levels remain within a optimal range.

MAT2 is a member of the DNA binding protein superfamily, which includes proteins that interact with DNA to regulate gene expression and DNA replication. MAT2 is primarily localized to the nucleus, where it is responsible for regulating the levels of histone H3 lysine 27 (H3K27) on the alpha-globin gene. H3K27 is a histone that plays a structural role in organizing DNA in the nucleus, and its levels are regulated by a variety of factors, including MAT2.

MAT2 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, MAT2 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This increase in MAT2 levels can lead to the development of cancer-promoting behaviors, such as cell proliferation, migration, and invasion.

In addition to its role in cancer, MAT2 has also been shown to contribute to the development of neurodegenerative diseases. For example, MAT2 has been shown to be overexpressed in the brains of individuals with Alzheimer's disease, and this increase in MAT2 levels has been linked to the development of neurodegeneration.

MAT2 has also been shown to play a role in the development of autoimmune disorders. For example, MAT2 has been shown to be overexpressed in the T cells of individuals with rheumatoid arthritis, and this increase in MAT2 levels has been linked to the development of autoimmune disease.

Despite its involvement in these diseases, MAT2 has also been shown to have potential as a drug target or biomarker. For example, MAT2 has been shown to be a potential drug target in cancer, as MAT2 inhibitors have been shown to have anti-cancer properties . In addition, MAT2 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, MAT2 is a protein that plays a crucial role in the regulation of methionine levels in the body. MAT2 is a member of the DNA binding protein superfamily and is primarily localized to the nucleus, where it regulates the levels of histone H3 lysine 27 on the alpha-globin gene. MAT2 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Given its involvement in these diseases, MAT2 has potential as a drug target or biomarker . Further research is needed to fully understand the role of MAT2 in disease and to develop effective treatments.

Protein Name: Methionine Adenosyltransferase II

The "Methionine adenosyltransferase II Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Methionine adenosyltransferase II comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets